Publications by authors named "Marleen Bouhuys"
Article Synopsis
- Infliximab is used to treat inflammatory bowel disease (IBD) and its trough concentrations (C-troughs) are important for optimizing treatment efficacy, traditionally measured using ELISA tests.
- A study compared the new Quantum Blue® lateral flow test with traditional ELISA for measuring C-troughs in 100 young IBD patients and found that both methods had good agreement, particularly in low-range measurements.
- The results indicated that lateral flow tests are a reliable, quicker alternative to ELISA, allowing for timely dose adjustments in patients experiencing active disease.
Ustekinumab is used off-label in pediatric Crohn's disease refractory to anti-tumor necrosis factor. Data on optimal dosing, target trough levels, and potential benefit of therapeutic drug monitoring in children treated with ustekinumab are limited. We describe a series of six adolescents who consented to be treated with ustekinumab.
View Article and Find Full Text PDFInflammatory bowel diseases (IBDs) are chronic, immune-mediated disorders that include Crohn's disease and ulcerative colitis. A pediatric onset of disease occurs in about 10% of all cases. Clinical presentation of IBD with rectal bleeding or perianal disease warrants direct referral for endoscopic evaluation.
View Article and Find Full Text PDFArticle Synopsis
- Long-term use of anti-TNF-α agents can lead to infections and skin reactions, and this study reviews whether reducing the dose or extending intervals can lessen these effects.
- A systematic review included 14 randomized controlled trials and 6 observational studies with a total of 2706 patients suffering from conditions like rheumatoid arthritis and psoriasis.
- Results indicate that de-escalation strategies did not significantly lower the rates of infections or skin manifestations compared to standard dosing, and inconsistencies in reporting limited deeper analysis.
Article Synopsis
- Anti-tumour necrosis factor (TNF) therapy improves treatment for inflammatory bowel disease (IBD) but comes with risks like skin reactions and infection susceptibility; dose reduction might be possible if flares are detected early.
- This study will compare lengthening medication intervals to standard dosing in 148 patients aged 12-25 with Crohn's disease or ulcerative colitis in remission, measuring how well both methods maintain remission over 48 weeks.
- The trial has ethical approval and aims to share findings through peer-reviewed journals and scientific presentations, with results focusing on disease activity and treatment safety.
Small-vessel vasculitis (SVV) is a rare immunological disease that affects arterioles, capillaries and venules. It causes purpura, but can also manifest in other organs, including the gastrointestinal tract. SVV and inflammatory bowel disease (IBD) co-occur more frequently than would be expected by chance.
View Article and Find Full Text PDF